ライフサイエンスコーパス: PCO

1 PCO analysis revealed clear genetic differentiation of t

2 PCO cardioplegia attenuated the intracellular increase i

3 PCO characteristics are extensive extracellular matrix (

4 PCO development and the influence of the anterior capsul

5 PCO incidence was higher in: (1) eyes operated on by jun

6 PCO is caused by residual lens cells undergoing one of t

7 PCO measurement compared well with the lithium dilution

8 PCO pretreatment improved LV myocyte contractile functio

9 PCO was evaluated clinically and histopathologically.

10 PCO(2) was determined by measuring the rate of intracell

11 PCOs address only the topics specifically identified in

12 PCOs are not continually updated and may not reflect the

13 PCOs are not continually updated and may not reflect the

14 PCOs are not continually updated and may not reflect the

15 PCOs are not continually updated and may not reflect the

16 PCOs cannot account for individual variation among patie

17 PCOs cannot account for individual variation among patie

18 PCOs cannot account for individual variation among patie

19 PCOs cannot account for individual variation among patie

20 y reperfusion and rewarming (n = 8); and (2) PCO/cardioplegia: institution of CPB, antegrade myocardi

21 espiratory stimuli include changes in PO(2), PCO(2), central respiratory drive, or respiratory mechan

22 ive secondary analyses from RCTs in the 2012 PCO on providing palliative care services to patients wi

23 The 2012 PCO was based on a review of a randomized controlled tri

24 ll as secondary analyses of RCTs in the 2012 PCO, published from March 2010 to January 2016.

25 reperfusion and rewarming (n = 62); and (3) PCO/cardioplegia: 5 minutes of PCO treatment (50 mumol/L

26 w evidence may have emerged since the time a PCO was submitted for publication.

27 w evidence may have emerged since the time a PCO was submitted for publication.

28 w evidence may have emerged since the time a PCO was submitted for publication.

29 w evidence may have emerged since the time a PCO was submitted for publication.

30 Contractility after PCO cardioplegia was similar to normothermic values in c

31 blots assessed AKT/ERK involvement 2 h after PCO.

32 known about its effects on infarction after PCO.

33 unction were measured 48 h and 3 weeks after PCO.

34 matory reaction, capsular fibrosis, ACO, and PCO.

35 ore steeply when ventilation was altered and PCO(2) was constant.

36 that the proteasome can mediate cataract and PCO-associated changes and therefore is a novel target o

37 ous NaHCO(3) concentration (10(-5)-1 M), and PCO(2) (0-1 atm).

38 The relation between PCO morphology and PCO severity and the precapsulotomy and postcapsulotomy

39 reactivity of the 2-phosphaethynolate anion (PCO(-)) towards a cyclic trisilene (cSi3(Tip)4) is repor

40 Reactions of the 2-phosphaethynolate anion (PCO(-), 1) with ammonium salts quantitatively yielded ph

41 In this study, the effectiveness of another PCO, nicorandil, was investigated for several reasons.

42 Accordingly, adherence to any PCO is voluntary, with the ultimate determination regard

43 Accordingly, adherence to any PCO is voluntary, with the ultimate determination regard

44 Accordingly, adherence to any PCO is voluntary, with the ultimate determination regard

45 Accordingly, adherence to any PCO is voluntary, with the ultimate determination regard

46 Apparent PCO(2) of BCEC (0.0036 +/- 0.00023 cm/sec) was not diffe

47 atients were stratified into 5 mm Hg arrival PCO(2) increments.

48 The proportion of arrival PCO(2) values within the optimal range was lower for int

49 proved survival was observed for the arrival PCO(2) range 30-49 mm Hg.

50 Outcomes for patients with arrival PCO(2) values inside and outside this optimal range were

51 Patients with arrival PCO(2) values inside this optimal range had improved sur

52 Arterial PCO(2) is tightly regulated via changes in breathing.

53 ASCO PCOs describe the use of procedures and therapies in cli

54 ASCO PCOs describe the use of procedures and therapies in cli

55 ASCO PCOs describe the use of procedures and therapies in cli

56 ASCO PCOs describe the use of procedures and therapies in cli

57 +)(221-Kryptofix)] salts containing AsCO(-), PCO(-), and PCS(-) anions were successfully electrospray

58 gavage to 250 g male rats for 10 days before PCO and was continued afterward.

59 ether these influenced the agreement between PCO and LiCO methods.

60 The relation between PCO morphology and PCO severity and the precapsulotomy a

61 ty, whereas the curvilinear relation between PCO severity and logMAR indicates that logMAR is unaffec

62 er capsulotomy differs significantly between PCO types (p = 0.005, Kruskal-Wallis test).

63 Suppression of SFK activation blocked PCO, suggesting SFKs as a therapeutic target for the pre

64 cells that are sensitive to changes in brain PCO(2) or pH and contribute to the stimulation of breath

65 contour CO (PCO) method, CO was measured by PCO and by LiCO methods at 4, 8, 16, and 24 hrs.

66 We find pre-CAMP PCO(2) values of ~2000 parts per million (ppm), increasi

67 In human cells, PCO-C (250 mug/mL) inhibited the production of intracell

68 enchymal transition (EMT) that characterizes PCO were observed in the presence and absence of the mat

69 initial calibration of the pulse contour CO (PCO) method, CO was measured by PCO and by LiCO methods

70 als termed lo-CO (PCO = 0.08 atm) and hi-CO (PCO = 0.5 atm).

71 rr, PO2 approximately 120 Torr) and high CO (PCO approximately 550 Torr, PO2 approximately 120 Torr)

72 rate two different EPR signals termed lo-CO (PCO = 0.08 atm) and hi-CO (PCO = 0.5 atm).

73 investigated the use of principle component (PCO) analysis as one approach to elucidate population st

74 curves demonstrated a right shift in control PCO animals, whereas the (-)-epicatechin curves were com

75 ased on the model material PrxCe1-xO2-delta (PCO).

76 p-Methoxycinnamic diester (PCO-C) was identified, which has a crystalline, apolar s

77 The influence of the different PCO types and the IOL/PC distance on the total-pulse ene

78 concentration of atmospheric carbon dioxide (PCO(2)) are mostly unknown.

79 concentration of atmospheric carbon dioxide (PCO(2)) near the Triassic-Jurassic boundary.

80 oride are sufficiently suppressed for direct PCO(2) measurements in freshwater samples at pH 8.

81 resembling human polycystic ovarian disease (PCO) and a decrease in the ovarian primordial follicle p

82 We interpret each PCO(2) increase as a direct response to magmatic activit

83 understanding of how the IOL design effects PCO has also advanced.

84 s, after reductive elimination of the entire PCO group, the unprecedented [L2 Ge-GeL2 ] complex 3 in

85 In this study, we estimate PCO(2) from stable isotopic values of pedogenic carbonat

86 at rest and during exercise in 19 eucapnic (PCO(2) 40 +/- 3 mm Hg), and 13 hypercapnic (PCO(2) 52 +/

87 highest energy was required for the fibrosis PCO type, followed by mixed, pearl and late-postoperativ

88 documentation was performed and analyzed for PCO using Evaluation of Posterior Capsule Opacification

89 f IOL was the most important risk factor for PCO in this study, whereas intrinsic proliferative capac

90 ract patients, to determine risk factors for PCO and to investigate possible association with growth

91 The model for PCO in vitro consisted of an IOL placed on a membrane co

92 tudy also provides one possible solution for PCO by using polymethylmethacrylate (PMMA) implanted int

93 g novel potential therapeutic strategies for PCO, our findings extend the so-called TGFbeta paradox,

94 oherence tomography (OCT) as a technique for PCO analysis.

95 e potential to become an additional tool for PCO characterization.

96 n patients who did not receive treatment for PCO (median 75 years, p = 0.022).

97 Data on treatment/no treatment for PCO was obtained from 270 patients with a median follow-

98 ation is expected to overestimate functional PCO severity.

99 lysis software was used to objectively grade PCO density from standardized, high-resolution retroillu

100 ickly reduce her FET(CO(2)) to 4.2%, but her PCO(2) did not change after administration of acetazolam

101 intact ventilatory response to exercise; her PCO(2) was high at the start of exercise and increased s

102 High PCO caused a highly significant rise in [Ca2+]i from 90+

103 High PCO did not change pHi at PO2 of 120-135 Torr, showing t

104 We measured the effect of high PCO (500-550 Torr) on the pHi and [Ca2+]i in cultured gl

105 (PCO(2) 40 +/- 3 mm Hg), and 13 hypercapnic (PCO(2) 52 +/- 10 mm Hg) patients with severe COPD.

106 (PO(2)=10-15 Torr) increased and hypocapnia (PCO(2)=7-9 Torr) decreased the cytoplasmic calcium [Ca(2

107 No significant change in PCO was observed between 3 and 5 years within the capsul

108 The systematic decreases in PCO(2) after each magmatic episode probably reflect cons

109 ed a statistically significant difference in PCO and neodymium:yttrium-aluminum-garnet capsulotomy ra

110 The increase in PCO up to 3 years was significant.

111 There was a significant increase in PCO up to 3 years.

112 As occurs in PCO, lens cells in this model proliferated, migrated acr

113 A rise in PCO(2) activates the carotid bodies and exerts additiona

114 Stabilization in PCO was observed between 3 and 5 years with no differenc

115 d the posterior lens capsule seem to inhibit PCO to a greater degree.

116 red at 130-136 days gestation failed to keep PCO(2) below 100 mm Hg by 2 hours.

117 Li-PCO and Li-CCO values were lower than simultaneously obt

118 Li-PCO gives a measurement that agrees well with Li-CCO.

119 Li-PCO provides accurate measurements of CO without the ris

120 6-11.52 L/min (mean, 5.22 L/min; n = 31); Li-PCO, 1.63-9.99 L/min (mean, 5.22 L/min; n = 31), and TDC

121 ood linear correlation between Li-CCO and Li-PCO (R2 =.845).

122 Serial measurements of Li-CCO and Li-PCO were made during hemodynamically stable conditions.

123 The mean difference for Li-CCO-Li-PCO was smaller if the peripheral injection site was pro

124 The mean difference for Li-CCO-Li-PCO was very small and insignificant (p =.97), and the l

125 enous administration of lithium chloride (Li-PCO) with Li-CCO.

126 imultaneously obtained TDCO measurements (Li-PCO-TDCO, -0.538 +/- 0.95 L/min, p =.003; Li-CCO-TDCO, -

127 Accuracy of Li-PCO is probably improved if a proximal arm vein is used.

128 There were 93 Li-CCOs, 93 Li-PCOs, and 216 TDCOs recorded.

129 R indicates that logMAR is unaffected by low PCO severity.

130 s) indicates that log(s) is sensitive to low PCO severity, whereas the curvilinear relation between P

131 d the hyperemic response to elevated luminal PCO(2) in the duodenum of anesthetized rats luminally ex

132 vides a therapeutic target to further manage PCO development and will yield best results when used in

133 In group A, the mean PCO score was significantly lower in the SE-PMMA IOL eye

134 In group B, the mean PCO score was statistically lower in the SE-PMMA IOL eye

135 etalloproteinases (MMPs) in TGFbeta-mediated PCO formation.

136 l endothelial cells (BCECs) affects membrane PCO(2).

137 rent arteriolar dilator response to 1 microM PCO-400 (a benzopyran K(ATP) agonist) was also accentuat

138 Predominantly mild PCO occurred in one-third of eyes after phacoemulsificat

139 ia: institution of CPB, antegrade myocardial PCO perfusion without recirculation (500 mL of 50 mumol/

140 The objective PCO score (mean +/- standard deviation) was 3.0 +/- 2.0

141 licates many features of clinically-observed PCO.

142 function after permanent coronary occlusion (PCO) and the potential involvement of the protective pro

143 thoracotomy and treatment in the absence of PCO.

144 IOL) designs that have reduced the amount of PCO following surgery have been made.

145 Thus the application of PCO pretreatment as a protective strategy in the setting

146 Associations of PCO with surgeon groups and different types of implanted

147 referral, especially in less severe cases of PCO.

148 r histopathological differences in degree of PCO between the TGF-beta2- and FCS/PBS-treated groups at

149 has the potential to suppress development of PCO and provide potential therapeutic benefit to catarac

150 good candidates for blocking development of PCO.

151 Comparisons of the EAs of PCO(*) and PCS(*) with the previously measured EA values

152 cond study determined whether the effects of PCO pretreatment could be translated to an in vivo model

153 The first study quantified the effects of PCO pretreatment on LV myocyte contractility after simul

154 nder the IOL and preventing the formation of PCO after cataract surgery.

155 d by TGF-beta2 and SPARC in the formation of PCO.

156 of the ECM-cell interaction in formation of PCO.

157 ctron density from phosphorus in the HOMO of PCO(-) to sulfur in the HOMO of PCS(-).

158 There was a low incidence of PCO in eyes with total anterior capsule cover over the I

159 Three-year cumulative incidence of PCO was 38.5% (95% confidence interval [CI] 36.1%-40.9%)

160 The three-year cumulative incidence of PCO was 5.2% and the cumulative 5-year incidence was 11.

161 Cumulative incidence of PCO was estimated using Kaplan-Meier methods.

162 Additionally, we evaluate the influence of PCO types and the distance between the intraocular lens

163 62); and (3) PCO/cardioplegia: 5 minutes of PCO treatment (50 mumol/L, SR47063, 37 degrees C; n = 94

164 P < 0.05) and was improved with 5 minutes of PCO treatment (58 +/- 3 microns/s).

165 to study mechanisms involved in the onset of PCO.

166 ctrochemically pumping oxygen into or out of PCO films, leading to measurable film volume changes due

167 tial therapeutic target in the prevention of PCO.

168 s a therapeutic target for the prevention of PCO.

169 Progression of PCO involved early activation of SFKs.

170 of UDVA and BDVA as well as similar rates of PCO after cataract surgery.

171 elastics were utilized ex vivo, and rates of PCO formation were analyzed.

172 Recalibration of PCO was performed every 8 hrs.

173 ular lens (IOL) were associated with risk of PCO, with hydrophilic 1-piece IOLs conferring a higher r

174 ovides a novel strategy for the treatment of PCO and potentially other fibrotic disorders.

175 The cardioprotective properties of PCOs are associated with an increased myocardial oxygen

176 t of TGF-beta2 or anti-TGF-beta2 antibody on PCO was found in rodents at the dose and timing administ

177 ion of the effects of SPARC and TGF-beta2 on PCO in vitro.

178 red the role of growth factor restriction on PCO using human lens cell and tissue culture models.

179 x (ECM) in posterior capsular opacification (PCO) in vitro.

180 Posterior capsular opacification (PCO) is caused by the proliferation, migration, and epit

181 ibition on posterior capsular opacification (PCO) with the use of a pig eye capsular bag model.

182 agement of posterior capsular opacification (PCO).

183 lopment of posterior capsular opacification (PCO).

184 aracts and posterior capsular opacification (PCO).

185 (ACO), and posterior capsular opacification (PCO).

186 e long-term posterior capsule opacification (PCO) and neodymium-doped yttrium aluminium garnet (Nd:YA

187 Posterior capsule opacification (PCO) arises because of a persistent growth of lens epith

188 OL) design, posterior capsule opacification (PCO) arising from lens cell growth remains a major probl

189 ns disorder posterior capsule opacification (PCO) develops in millions of patients following cataract

190 Posterior capsule opacification (PCO) is a complication of cataract surgery resulting fro

191 Posterior capsule opacification (PCO) is the most common complication following primary c

192 Posterior capsule opacification (PCO) is the most common post-operative complication asso

193 effective, posterior capsule opacification (PCO) occurs in 30-50% of patients following modern catar

194 lication of posterior capsule opacification (PCO) or secondary cataract.

195 ncidence of posterior capsule opacification (PCO) requiring Nd:YAG laser capsulotomy in a representat

196 symptomatic posterior capsule opacification (PCO) underwent Nd:YAG laser capsulotomy.

197 e, known as posterior capsule opacification (PCO), following cataract surgery.

198 ributing to posterior capsule opacification (PCO).

199 nt model of posterior capsule opacification (PCO).

200 re model of posterior capsule opacification (PCO).

201 surgery is posterior capsule opacification (PCO; secondary cataract).

202 hosphate-sensitive potassium channel opener (PCO)-induced hyperpolarized arrest with pinacidil minimi

203 ssium channels by potassium channel openers (PCO) within the myocyte appears to confer a protective e

204 nstrated that the potassium channel openers (PCOs) aprikalim and pinacidil are effective cardioplegic

205 Pretreatment with potassium channel openers (PCOs) has been shown to provide protective effects in th

206 nical Oncology Provisional Clinical Opinion (PCO) offers timely clinical direction after publication

207 ncology (ASCO) provisional clinical opinion (PCO) offers timely clinical direction to ASCO's membersh

208 ncology (ASCO) provisional clinical opinion (PCO) offers timely clinical direction to ASCO's membersh

209 ncology (ASCO) provisional clinical opinion (PCO) offers timely clinical direction to ASCO's membersh

210 ncology (ASCO) provisional clinical opinion (PCO) offers timely clinical direction to the ASCO member

211 ncology (ASCO) provisional clinical opinion (PCO) on the integration of palliative care into standard

212 ncology (ASCO) provisional clinical opinion (PCO), offers timely clinical direction to ASCO's oncolog

213 Purpose ASCO provisional clinical opinions (PCOs) offer direction to the ASCO membership after publi

214 NOTE: ASCO's provisional clinical opinions (PCOs) reflect expert consensus based on clinical evidenc

215 ASCO's provisional clinical opinions (PCOs) reflect expert consensus based on clinical evidenc

216 ASCO's provisional clinical opinions (PCOs) reflect expert consensus based on clinical evidenc

217 ASCO's provisional clinical opinions (PCOs) reflect expert consensus based on clinical evidenc

218 ive survival were used to define the optimal PCO(2) range.

219 in outcomes for patients within this optimal PCO(2) range for nonintubated patients after adjusting f

220 ion to the evidence reviewed in the original PCO, 11 systematic reviews with meta-analyses, two retro

221 ructure of nicorandil is distinct from other PCOs, in part because of a nitrate moiety, which may con

222 In contrast to other PCOs, nicorandil produced mechanical arrest as quickly a

223 The PLANT CYSTEINE OXIDASEs (PCOs) have been identified as catalysts of this oxidatio

224 cyanide insensitive palmitoyl CoA oxidation (PCO) and caused activation of nuclear factor kappa beta

225 52 patients and nine normal subjects for pH, PCO(2), and concentrations of plasma electrolytes and pr

226 t the sensor is equally useful for gas-phase PCO(2) measurements.

227 the routine environmental and physiological PCO(2) levels.

228 The RE-PMMA PCO rate did not plateau and continued to increase throu

229 del coupled to a carbon-cycle model predicts PCO(2) increases of less than 400 ppm from magmatic vola

230 d whether the inhibition of SFKs can prevent PCO.

231 ibition as a therapeutic strategy to prevent PCO.

232 Therefore, exposure to PP1 prevented PCO.

233 the initial phospholane, reaction products (PCO/POC-isomers), and an intermediate P(V)-oxaphosphiran

234 le and posterior capsules and further reduce PCO incidence.

235 on in hypoxia presumably arises from reduced PCO activity.

236 hom information could be retrieved regarding PCO treatment, in vitro cell culture could be establishe

237 potential therapeutic approach to resolving PCO.

238 he linear relation between retroillumination PCO severity and log(s) indicates that log(s) is sensiti

239 ising out of or related to any use of ASCO's PCOs, or for any errors or omissions.

240 ising out of or related to any use of ASCO's PCOs, or for any errors or omissions.

241 ising out of or related to any use of ASCO's PCOs, or for any errors or omissions.

242 ising out of or related to any use of ASCO's PCOs, or for any errors or omissions.

243 Severe PCO was defined if the view of the optic disc was obscur

244 ncluding 4.7% (95% CI 3.5%-5.8%) with severe PCO.

245 ls seems to be less important for subsequent PCO development.

246 tion was related to PCO severity rather than PCO morphology.

247 We directly demonstrate that PCO dioxygenase activity produces Cys-sulfinic acid at t

248 Thermogravimetric analysis showed that PCO-C had high thermal stability and high UV absorption

249 The PCO controls received water.

250 The PCO plus (-)-epicatechin group values were comparable wi

251 The PCO scores and Nd:YAG capsulotomy rate.

252 The PCO severity (EPCO score) assessed with retroilluminatio

253 The PCO severity was assessed with retroillumination using e

254 tend to cause overestimation of LiCO by the PCO.

255 terised, including a compound containing the PCO(-) anion in an unprecedented mu(2) :eta(2) ,eta(2) -

256 ly the topics specifically identified in the PCO and are not applicable to interventions, diseases or

257 Progression of proliferation and EMT in the PCO cultures was determined by Western blot analysis and

258 However, in the PCO pretreatment group, 50% developed refractory ventric

259 In the PCO-pretreated animals, the PRSWR was higher after cessa

260 lution in dichloromethane for one month, the PCO-isomer rearranges into the thermodynamically more st

261 Mild hydrolysis of the PCO/POC-isomers proceeds with a high chemoselectivity an

262 ed hypercapnia, PET(CO(2)) overestimates the PCO(2) at the central chemoreceptors.

263 Our study indicates that the PCO types and the IOL/PC distance influence the total-pu

264 ificantly reduced in myocytes exposed to the PCO-supplemented cardioplegic solution (109+/-4 nmol/L,

265 haheteroallenes (NHP)-O-P=C=NHC in which the PCO unit has been isomerized to OPC.

266 The PCOs and ATE1 may be viable intervention targets to stab

267 This PCO addresses recommendations for chronic hepatitis B vi

268 This PCO addresses second-line hormonal therapy for chemother

269 This PCO addresses the clinical utility of using epidermal gr

270 This PCO addresses the integration of palliative care service

271 This PCO addresses the role of prostate-specific antigen (PSA

272 This PCO addresses the utility of KRAS gene mutation testing

273 This PCO update addresses the utility of extended RAS gene mu

274 als and expert consensus opinion inform this PCO.

275 ity systematic review primarily informs this PCO on the benefits and harms of PSA-based screening.

276 Seven published RCTs form the basis of this PCO.

277 hemotherapy doublets, form the basis of this PCO.

278 g growth factor beta (TGFbeta) is central to PCO development.

279 AQP1 does not contribute to PCO(2) in corneal endothelial cells.

280 The duodenal mucosa is exposed to PCO(2) >200 mm Hg due to the luminal mixture of gastric

281 ia that presents a significant limitation to PCO cardioplegia.

282 epithelial mesenchymal transition linked to PCO.

283 Visual function deterioration was related to PCO severity rather than PCO morphology.

284 of the contribution of calcium-signaling to PCO.

285 90 nM (n=6) at normoxia (PO(2)=125-130 Torr, PCO(2)=25-30 Torr, pH 7.30-7.35).

286 work and effort while independently varying PCO(2) or the level of targeted voluntary breathing.

287 ed HA resulted in increased rates of ex vivo PCO suggesting that judicious selection and use of visco

288 ions of HA led to increased rates of ex vivo PCO.

289 The main outcome measure was PCO score (scale, 0 to 10) assessed subjectively at the

290 At 3 weeks, PCO control animals demonstrated significant increases i

291 air hunger ratings changed more steeply when PCO(2) was altered and ventilation was constant; work or

292 of the present study was to examine whether PCO pretreatment would provide protective effects on lef

293 ence of added serum protein and explains why PCO is such a common problem even in aged patients.

294 ossible predisposing factors associated with PCO development include surgery performed by ophthalmolo

295 study population, 240 pseudophakic eyes with PCO and a capsulotomy indication were selected.

296 d width of the ACA in pseudophakic eyes with PCO increased significantly after Nd:YAG laser capsuloto

297 47 eyes with PCO scheduled for the Nd:YAG procedure were examined and

298 improvement in contractile performance with PCO pretreatment was confounded by refractory arrhythmog

299 nce population, 99 pseudophakic eyes without PCO were selected.

300 those of a control group of 15 eyes without PCO.